Cytomegalovirus antigenemia surveillance in the treatment of cytomegalovirus disease in AIDS patients

Journal of Chemotherapy

Volumn 11, Issue 3, 1999, Pages 195-202

  Carton, J A ^a,b   Rodriguez Guardado, A ^a   Melon, S ^a   Maradona, J A ^a   De Ona M ^a   Asensi, V ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

AIDS patients; Antigenemia; CMV antigenmia; Cytomegalovirus; Extraocular disease; Foscarnet; Ganciclovir; HIV infection; Retinitis

Indexed keywords

FOSCARNET; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PROSPECTIVE STUDY; RETINITIS; TREATMENT OUTCOME;

EID: 0033028629     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.3.195     Document Type: Article

References (22)

1. Ives DV. Cytomegalovirus disease in AIDS. AIDS 1977; 11: 1791-1797.
2. Francisci D, Tosti A, Baldelli F, Stagni G, Paulizzi S. The pp65 antigenaemia test as a predictor of cytomegalovirus-induced end-organ disease in patients with AIDS. AIDS 1997; 11: 1341-1345.
3. Dodt KK, Jacobsen PH, Hofmann B, et al. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS 1997; 11: F21-F28.
4. Shinkai M, Bozzete SA, Powderly W, Frame P, Spector SA, Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis 1997; 175: 302-308.
5. Bowen EF, Sabin CA, Wilson P, et al. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 1997; 11: 889-893.
6. Bowen EF, Wilson P, Cope A, et al. Cytomegalovirus retinitis in AIDS patients, influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 1996; 10: 1515-1520.
7. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or Ganciclovir. J Infect Dis 1997; 176: 50-58.
8. Manfredi R, Lazzarotto T, Spezzacatena P, et al. Quantitative cytomegalovirus (CMV) antigenemia during antiviral treatment of AIDS-related CMV disease. J Antimicrob Chemother 1997; 40: 299-302.
9. Ljungman P, Plotkin SA. Workshop on CMV disease: definitions, clinical severity scores and new syndromes. Scand J Infect Dis 1995; 99: 87-89.
10. Jacobson MA. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337: 105-114.
11. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD, and the Ganciclovir Implant Study Group. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997; 337: 83-90.
12. Hodinka R, Friedman HM. Human cytomegalovirus, In Ballows A, ed. Manual of Clinical Microbiology. 5th edition. Washington, DC: American Society for Microbiology, 1991: 829-837.
13. Pérez JL, De Oña M, Niubó J, Villar H, Melon S, García A, Martín R, Comparison of several fixation methods for cytomegalovirus antigenemia assay. J Clin Microbiol 1995; 33: 1646-1649.
14. Balfour HH, Fletcher CV, Erice A, et al. Effect of foscarnet on quantities of citomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrob Agents Chemother 1996; 40: 2721-2726.
15. Boivin G, Quirk MR, Kringstad BA, Germain M, Jordan MC. Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leukocytes of immunocompromised patients. Antimicrob Agents Chemother 1997; 41: 860-862.
16. Gerna G, Baldati A, Sarasini M, et al., and the Italian Foscarnet Study Group. Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. Antimicrob Agents Chemother 1994; 38: 38-44.
17. Payan Ch, Veal N, Sarol L, et al. Human cytomegalovirus DNA quantitative assay in white blood cells of immunocompromised patients under ganciclovir therapy. J Virolog Meth 1997; 65: 131-138.
18. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Ann Intern Med 1997; 126: 264-274.
19. Bek B, Boeckh M, Lepenies J, et al. High-level sensitivity of quantitative pp65 cytomegalovirus antigenemia assay for diagnosis of cytomegalovirus disease in Aids patients and follow-up. J Clin Microbiol 1996; 34: 457-459.
20. Boivin G, Chou S, Quirk MK, Erice A, Jordan MC. Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis 1996; 173: 523-528.
21. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326: 213-220.
22. Drew WL, Ives D, Lalezari JP, et al. for the Syntex Cooperative Oral Ganciclovir Study Group. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995; 333: 615-620,